Acute kidney injury (AKI) is a serious medical condition characterized by an abrupt loss of kidney function. AKI is estimated to affect up to 18 percent of hospital
Shopfloor-Online is a well-established, web-based product that has already been installed with hundreds of customers in different sectors across the world and the creation of the Lifescience edition
In the pivotal studies, Alecensa shrank tumors in up to 44 percent of people with ALK-positive NSCLC who progressed on crizotinib (objective response rate [ORR] of 38 percent
The proposed study, which will enroll approximately 75 patients, is projected to launch in Canada in Q2 2016. XBiotech medical director Michael Stecher said, "This program represents the
The candidate, CX-2009, is a first-in-class Probody drug conjugate targeting CD166. CX-2009 utilizes ImmunoGen, Inc. conjugate technology. CytomX chief scientific officer Michael Kavanaugh said: "CD166 is highly and
The collaboration aims to develop new technologies for biologics production and to identify new targets for disease research in the ground-breaking area of the Secretome – research into
The meeting with the FDA concerned the company’s cell-based product for the treatment of ALS. The response received on December 9, 2015 from the FDA represents a summary
"The ADAPT phase 3 trial to evaluate AGS-003 in front line mRCC, the largest global trial ever performed in newly diagnosed, unfavorable risk mRCC patients, continues to progress
If approved, the sNDA would expand the approved use of IBRANCE to reflect findings from the Phase 3 PALOMA-3 trial, which evaluated IBRANCE in combination with fulvestrant versus
The Company is developing TD-1473 as an investigational compound with the potential to treat a range of inflammatory intestinal diseases. TD-1473 is an internally-discovered JAK inhibitor that has
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.